Ivabradine Anpharm 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
WS/2569 
This was an application for a variation following a 
14/12/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
authorisation, including the RMP - Other variation 
PSUSA/1799/
Periodic Safety Update EU Single assessment - 
30/11/2023 
n/a 
PRAC Recommendation - maintenance 
202304 
ivabradine 
IG/1674 
B.I.b.2.a - Change in test procedure for AS or 
06/11/2023 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IG/1670 
B.I.a.2.a - Changes in the manufacturing process of 
12/10/2023 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IAIN/0017/G 
This was an application for a group of variations. 
27/01/2023 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
N/0016 
Minor change in labelling or package leaflet not 
20/10/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/1799/
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
202004 
ivabradine 
R/0014 
Renewal of the marketing authorisation. 
26/03/2020 
20/05/2020 
Based on the review of data on quality, safety and efficacy, 
including all variations introduced since the marketing 
authorisation was granted, the benefit-risk balance of 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ivabradine Anpharm in its approved indication(s) (please 
refer to the Summary of Product Characteristics) remains 
favourable and therefore the renewal of the marketing 
authorisation is recommended, subject to the conditions as 
detailed in Annex II. 
The renewal is recommended to be granted with unlimited 
validity. 
WS/1641 
This was an application for a variation following a 
11/07/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
N/0012 
Notification 
14/06/2019 
20/05/2020 
PL 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IA/0011 
A.7 - Administrative change - Deletion of 
12/04/2019 
n/a 
manufacturing sites 
SW/0010 
18/10/2018 
07/01/2019 
Annex II 
The results of this DUS study showed an increase in 
adherence to the SmPC guidelines in the post-RMM period 
compared to the pre-RMM period. This increase in 
adherence was measured for all the four criteria under 
study. Therefore, in view of available data regarding the 
PASS final study report, the PRAC considered that changes 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/1799/
Periodic Safety Update EU Single assessment - 
29/11/2018 
n/a 
PRAC Recommendation - maintenance 
201804 
ivabradine 
WS/1352/G 
This was an application for a group of variations 
03/05/2018 
n/a 
to the conditions of the marketing authorisation were 
warranted. 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
WS/1180 
This was an application for a variation following a 
11/01/2018 
07/01/2019 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
Update of the RMP with current information on 
epidemiology, post-authorisation exposure and post 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
authorisation studies status including the due date of 
the final study report for Ivabradine Drug Utilisation 
Study. The Annex II has been updated accordingly. 
In addition the MAH took the opportunity to align the 
PI with the latest QRD template 10.0 and introduce 
minor updates to the ADR terms. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/1799/
Periodic Safety Update EU Single assessment - 
30/11/2017 
n/a 
PRAC Recommendation - maintenance 
201704 
ivabradine 
PSUSA/1799/
Periodic Safety Update EU Single assessment - 
01/12/2016 
n/a 
PRAC Recommendation - maintenance 
201604 
ivabradine 
WS/0932/G 
This was an application for a group of variations 
07/07/2016 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IAIN/0004 
C.I.11.a - Introduction of, or change(s) to, the 
06/07/2016 
08/05/2017 
Annex II 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
WS/0914 
This was an application for a variation following a 
28/04/2016 
08/05/2017 
SmPC, Annex 
In this variation the MAH updated the Product information 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
II, Labelling 
to indicate that to date there is no evidence of a toxic effect 
and PL 
of long-term ivabradine treatment on the retina. 
Update of sections 4.4 and 5.1 of the SmPC in order 
to update the information on retinal safety. In 
addition, the Marketing authorisation holder (MAH) 
took the opportunity to bring the PI in line with the 
latest QRD template version 9.1. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
